Avior Bio News Today

Avior Bio, a small Cary startup developing a treatment for pruritus, or chronic itchy skin, has secured an agreement to license its clinical-stage therapy to a New Jersey pharmaceutical company.

Gainers Senti Biosciences, Inc. (NASDAQ: SNTI) shares surged 120.8% to $0.6450 in pre-market trading after the company reported a new strategic collaboration with Celest Therapeutics for the clinical development of SENTI-301A in China.

U.S. stocks traded mixed this morning, with the Dow Jones falling around 50 points on Tuesday Following the market opening Tuesday, the Dow traded down 0.18% to 34,035.79 while the NASDAQ rose 0.14% to 13,537.65. The S&P 500 also fell, dropping, 0.22% to 4,356.26.

U.S. stocks traded higher midway through trading, with the Nasdaq Composite gaining more than 100 points on Tuesday The Dow traded up 0.19% to 34,159.14 while the NASDAQ rose 0.84% to 13,631.99. The S&P 500 also rose, gaining, 0.30% to 4,379.06.

Gainers PaxMedica, Inc. (NASDAQ: PXMD) shares climbed 173.8% to $8.35. PaxMedica announced the publication of its autism spectrum disorder Phase 2 study results in the Annals of General Psychiatry.

Tharimmune Executes Exclusive Global Licensing Agreement for Innovative ...

Impact investing is on the rise, and local pharmaceutical industry insiders presenting as part of a “who’s who” speaker lineup at LaunchBio’s recent Invest in Cures forum say it’s already paying off.